Laura M. Pizzuti
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 130 publications
Corrigendum to "A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma" [Exp Mol Pathol Volume 146, June 2026, 105049].
Journal: Experimental and molecular pathology
Published: May 28, 2026
A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma.
Journal: Experimental and molecular pathology
Published: January 26, 2026
Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study.
Journal: NPJ breast cancer
Published: January 23, 2026
Author Correction: Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.
Journal: Nature immunology
Published: September 17, 2024
DNA Damage Response in Early Breast Cancer: A Phase III Cohort in the Phobos Study.
Journal: Cancers
Published: June 26, 2024
Breast and cervical cancer in transgender men: literature review and a case report.
Journal: Therapeutic advances in medical oncology
Published: January 30, 2024
HER2 mutation as an emerging target in advanced breast cancer.
Journal: Cancer science
Published: January 15, 2024
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study.
Journal: Neoplasia (New York, N.Y.)
Published: September 13, 2023
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study.
Journal: Frontiers in oncology
Published: March 01, 2023
Last Updated: 09/26/2026